NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
FDC Secures ₹20.71 Cr Income Tax Refund for AY 2013-14 Following Favourable CIT(A) Order
FDC Limited has received an order from the Assistant Commissioner of Income Tax determining an aggregate refund of ₹20.71 crore for Assessment Year 2013-14. This follows a favourable ruling by the Commissioner of Income Tax Appeals (CIT(A)) dated September 29, 2026, which overturned disallowances relating to publicity expenses and Section 14A. The ₹20.71 crore refund represents approximately 7.1% of FDC's TTM PAT of ₹291 crore. The company stated that interest income included in the refund amount will be credited to the Profit and Loss statement as income.
உச்சம் நம்பிக்கை
என்ன மாறியதுFDC secured a favourable tax appeal order resulting in an official tax refund determination of ₹20.71 crore for AY 2013-14.
ஏன் இது முக்கியம்The refund provides a one-time cash inflow of ₹20.71 crore (~7.1% of TTM PAT) and will boost reported other income via the accrued interest component.
Determined Tax Refund: Rs. 20.71 CrRefund as % of TTM PAT: ~7.1%Refund as % of TTM Revenue: ~0.9%Assessment Year: AY 2013-14
📅 குறுகிய காலம்Positive for cash flow and reported quarterly other income once recognized; no change to core operational performance.
📈 நீண்ட காலம்Limited; this is a one-time resolution of a legacy tax dispute from AY 2013-14.
⚠ அபாய எச்சரிக்கைகள்
Tax department may potentially contest or appeal the CIT(A) order before the Income Tax Appellate Tribunal (ITAT)
👀 கவனிக்க வேண்டியவை
Watch for the exact interest income portion of the refund in upcoming quarterly results and cash flow statements to track when the refund proceeds are realized.
FDC Secures ₹37.22 Cr Income Tax Refund Following Favourable CIT(A) Orders
FDC Limited has received appeal effect orders from the Assistant Commissioner of Income Tax following favourable rulings by CIT(A) for Assessment Years 2012-13 and 2014-15. The orders determine an aggregate tax refund of ₹37.22 crore in favor of the company. The disputes pertained to disallowances made by the Assessing Officer concerning publicity expenses and Section 35(2AB) scientific research deductions. The refund amount represents approximately 12.8% of FDC's TTM net profit of ₹291 crore, and interest accrued on the refund will be recognized as other income in the Statement of Profit and Loss.
உச்சம் நம்பிக்கை
என்ன மாறியதுCIT(A) ruled in favour of FDC for AY 2012-13 and AY 2014-15, leading the Assessing Officer to issue refund orders aggregating to ₹37.22 crore.
ஏன் இது முக்கியம்Provides a one-time cash inflow equivalent to ~12.8% of annual TTM net profit (₹291 Cr) and an additional P&L boost through credited refund interest.
Total refund amount: Rs.37.22 CrRefund vs TTM PAT: ~12.8%Assessment Years involved: AY 2014-15 and AY 2012-13
📅 குறுகிய காலம்Positive cash-flow boost in the near term; other income line will reflect interest income in the relevant upcoming quarter.
📈 நீண்ட காலம்Limited; this is a one-time tax dispute resolution with no material change to operational earnings capacity.
⚠ அபாய எச்சரிக்கைகள்
Department could potentially challenge the CIT(A) orders at higher appellate tribunals (ITAT)
👀 கவனிக்க வேண்டியவை
Track the recognition of interest income and cash realization from the refund in subsequent quarterly financial statements.
FDC Announces ₹120 Cr Share Buyback at ₹500/Share via Tender Offer
FDC Limited has issued a Public Announcement for a share buyback of up to 24,00,000 equity shares at ₹500 per share via a tender offer. The aggregate buyback consideration is up to ₹120.00 crore, which represents approximately 1.94% of the current market capitalization and 4.87% of consolidated net worth/reserves. The offer price of ₹500 represents a ~31% premium over the recent trading price of ₹381.7. The record date to determine eligible shareholders has been fixed as Friday, November 13, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுFDC has officially released the detailed public announcement and timeline details for its ₹120 crore share buyback.
ஏன் இது முக்கியம்The buyback returns surplus cash to shareholders at a ~31% premium to market price and marginally enhances EPS and return ratios by extinguishing up to 24 lakh shares.
Buyback Price: ₹ 500Buyback Size: ₹ 120.00 CroreShares to be acquired: 24,00,000ரெக்கார்ட் தேதி: வெள்ளி, நவம்பர் 13, 2026Buyback size vs Market Cap: ~1.94%
📅 குறுகிய காலம்The ~31% premium to market price is likely to provide near-term price support leading up to the November 13, 2026 record date.
📈 நீண்ட காலம்Limited structural change given the modest size (~1.94% of equity base), but it signals disciplined capital allocation and solid balance sheet liquidity.
⚠ அபாய எச்சரிக்கைகள்
Acceptance ratio uncertainty depending on promoter and retail participation levels
👀 கவனிக்க வேண்டியவை
Eligible shareholders should track the Record Date of November 13, 2026, and await the tender offer schedule and Letter of Offer for the exact entitlement ratio and tendering window.
FDC Approves ₹120 Cr Share Buyback at ₹500/Share; Q2 Standalone Revenue at ₹552.79 Cr
FDC Limited's Board has approved a tender offer buyback of up to 24,00,000 equity shares (1.47% of paid-up capital) at ₹500 per share, totaling up to ₹120.00 crore. The buyback price represents a 41.3% premium over the market price of ₹353.8, with the record date set for November 13, 2026. Simultaneously, Q2 FY27 standalone revenue from operations came in at ₹552.79 crore (compared to ₹617.74 crore in Q2 FY26) with net profit at ₹49.86 crore (versus ₹29.48 crore in Q2 FY26). Promoters hold a 69.66% stake and have confirmed their intention to participate in the buyback.
உச்சம் நம்பிக்கை
என்ன மாறியதுFDC announced a ₹120 crore share buyback at a 41.3% premium to market price and published its Q2 FY27 unaudited financial results.
ஏன் இது முக்கியம்The ₹120 crore buyback represents a return of surplus capital to shareholders, boosting EPS slightly, while standalone Q2 net profit improved year-on-year to ₹49.86 crore.
Buyback Offer Size: ₹120.00 CroresBuyback Price: ₹ 500/- per shareShares to be bought back: 24,00,000Buyback size vs Market Cap: ~2.09%ரெக்கார்ட் தேதி: நவம்பர் 13, 2026Q2 Standalone Revenue: ₹55,279 லட்சம்
📅 குறுகிய காலம்The substantial 41.3% premium on the buyback offer price is likely to provide near-term price support ahead of the November 13, 2026 record date.
📈 நீண்ட காலம்Limited; the buyback extinguishes 1.47% of shares, which incrementally enhances capital efficiency without altering core pharma operating fundamentals.
⚠ அபாய எச்சரிக்கைகள்
Promoter participation implies a portion of the buyback proceeds will accrue to the promoter group rather than solely increasing retail ownership concentration.
Standalone revenue declined year-on-year from ₹617.74 crore to ₹552.79 crore.
👀 கவனிக்க வேண்டியவை
Investors should track the record date on November 13, 2026, and look out for the upcoming public announcement detailing the tender offer ratio and acceptance entitlement.
FDC Q2 FY27 Results: PAT Up 72.9% YoY to Rs 49 Cr; Revenue Rises 21.0% to Rs 572 Cr
FDC Limited reported a 21.0% YoY increase in consolidated revenue from operations to Rs 572 crore for Q2 FY27, compared to Rs 473 crore in Q2 FY26. Consolidated net profit rose 72.9% YoY to Rs 49 crore, with EPS increasing to Rs 3.01 from Rs 1.75. Growth was anchored by Domestic Formulations, which grew 22.6% YoY to Rs 467 crore led by Electral, Enerzal, and recovery in Zifi. Operating margins improved meaningfully, with EBITDA margin expanding by 410 bps YoY to 11.2% (EBITDA of Rs 64 crore).
உச்சம் நம்பிக்கை
என்ன மாறியதுFDC returned to double-digit growth in Q2 FY27, driven by a rebound in Domestic Formulations and a doubling of US formulation sales.
ஏன் இது முக்கியம்The performance marks a sharp operational turnaround from the depressed base of Q2 FY26, bringing EBITDA margins back to 11.2% and expanding H1 FY27 PAT by 21.3% to Rs 181 crore.
📅 குறுகிய காலம்The strong bounce back in operating margins and top-line growth provides positive momentum following recent quarters of subdued margin performance.
📈 நீண்ட காலம்Sustained momentum in core domestic brands (Electral, Enerzal, Zifi) combined with international market penetration will be key to sustaining double-digit sales growth.
⚠ அபாய எச்சரிக்கைகள்
API business registered a slight contraction (-4.8% YoY in Q2) due to lower sales of a key molecule
Historical volatility in US revenues and profitability due to product recalls
👀 கவனிக்க வேண்டியவை
Track whether the recovery in flagship brands like Zifi and operating margin expansion to double digits can be sustained in the traditionally softer second half of the fiscal year.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
FDC Secures Delhi High Court Interim Stay on FSSAI Notice; Gets 8 Months to Exhaust Stock
FDC Limited has obtained an interim stay from the High Court of Delhi against an impugned notice issued by FSSAI concerning product mislabeling ('electrolyte'/'electrolyte drink'). The court order, received on August 26, 2026, allows FDC an 8-month window to exhaust its existing inventory and update product labels accordingly. This follows a previous stock seizure intimation dated June 4, 2026 by FSSAI Maharashtra. Management confirmed there is no material adverse financial or operational impact from this order.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe High Court granted an interim stay against FSSAI's regulatory notice, providing an 8-month transition window to clear existing stock and update packaging.
ஏன் இது முக்கியம்Averts immediate product write-offs or sales disruption for energy/electrolyte formulations, ensuring smooth operational continuity for domestic sales.
Transition period granted: 8 மாதங்கள்Order receipt date: 26th ஆகஸ்ட், 2026TTM Revenue context: Rs 2191 கோடி
📅 குறுகிய காலம்Removes immediate regulatory overhang and prevents disruption in the distribution of affected SKUs.
📈 நீண்ட காலம்Limited long-term financial impact as relabeling within 8 months should normalize regulatory compliance without recurring costs.
⚠ அபாய எச்சரிக்கைகள்
Pending final outcome of the Writ Petition before the Delhi High Court
Execution risk in updating packaging across distribution channels within 8 months
👀 கவனிக்க வேண்டியவை
Track the execution of product label transitions over the next 8 months and any final rulings from the Delhi High Court regarding FSSAI compliance.
FDC Subsidiary Receives UK MHRA Approval for Atropine 1.0% Eye Drops
FDC Limited's subsidiary, FDC International Ltd, has received Marketing Authorisation from the UK MHRA for Atropine 1.0% w/v Eye Drops. This approval aligns with the company's stated strategy to aggressively target non-US markets like Europe to increase its export revenue, which currently stands at approximately 13% of formulations. Given FDC's TTM revenue of ‹2,171 Cr, this specific product approval strengthens its core ophthalmic portfolio in a regulated market. This comes at a time when the company is looking to offset a 31.2% decline in US revenue observed in H1 FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுFDC has obtained regulatory clearance to market its Atropine 1.0% Eye Drops in the United Kingdom, expanding its international product footprint.
ஏன் இது முக்கியம்This approval supports FDC's strategy to diversify its geographic risk, especially after recent revenue headwinds in the US market, and leverages its established expertise in ophthalmic formulations.
📅 குறுகிய காலம்The news is sentimentally positive for the stock as it validates the company's R&D and regulatory capabilities in a stringent market like the UK.
📈 நீண்ட காலம்Structurally, this adds to FDC's portfolio in the high-margin ophthalmic segment and contributes to the long-term goal of outperforming the Indian Pharmaceutical Market growth rate through international expansion.
⚠ அபாய எச்சரிக்கைகள்
Market competition in the UK for Atropine drops
Pricing pressure in regulated markets
Execution risk in international distribution
👀 கவனிக்க வேண்டியவை
Investors should monitor the commercial launch timeline in the UK and track the growth in 'Export Formulations' in upcoming quarterly results to gauge the product's contribution.
9.2% PAT Growth in Q1 FY27; US Business Surges 118% Amid Muted Domestic Sales
FDC reported a modest 3% YoY revenue growth to 668 crore for Q1 FY27, primarily driven by a sharp recovery in international markets. While the core Domestic Formulations segment (85% of sales) saw a 1.9% decline due to subdued performance in key brands like Zifi and Enerzal, the US business grew 118.4% to 34 crore. Profit After Tax (PAT) rose 9.2% to 132 crore, maintaining a healthy margin profile. The company also secured a key US FDA approval for Cefixime Oral Suspension during the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுFDC's growth engine shifted from domestic to international markets this quarter, with the US and Non-US exports offsetting a rare decline in the domestic formulations business.
ஏன் இது முக்கியம்Domestic formulations are FDC's primary value driver (85% of revenue); while international growth is positive, the company needs domestic stability to maintain its historical outperformance of the Indian Pharmaceutical Market.
Q1 வருவாய்: 668 crQ1 PAT: 132 crUS Business Growth: 118.4%Domestic Sales Contribution: 85%Q1 வருவாய் vs TTM வருவாய்: 30.8%
📅 குறுகிய காலம்The stock may see neutral to slightly cautious sentiment as the market digests the decline in the core domestic segment despite the bottom-line growth.
📈 நீண்ட காலம்FDC's strategy to expand its field force and target non-US markets remains structural; long-term value depends on returning the domestic business to its 14.5% historical growth trajectory.
⚠ அபாய எச்சரிக்கைகள்
Decline in core domestic formulations revenue
Subdued performance of high-margin flagship brands
High concentration in domestic market (85%)
👀 கவனிக்க வேண்டியவை
Monitor the recovery of domestic flagship brands (Zifi, Enerzal) in upcoming quarters and the sustainability of the US business growth following the new Cefixime approval.
₹132 Cr Q1 Profit: FDC Reports 9% YoY Growth and Green Energy Investment
FDC Limited reported a steady Q1 FY27 with consolidated revenue growing 4.6% YoY to ₹715.35 cr. Net profit increased by 9.1% to ₹132.39 cr, resulting in an EPS of ₹8.14 compared to ₹7.45 in the previous year's corresponding quarter. Additionally, the board approved a ₹45 lakh investment for a 26% stake in Netra Green Energy to procure solar power for its Roha API plant. This investment is negligible at approximately 0.02% of the company's ₹2,492 cr net worth but aligns with long-term cost-optimization strategies.
உச்சம் நம்பிக்கை
என்ன மாறியதுFDC delivered a growth-oriented Q1 and initiated a strategic move toward captive green energy for its API manufacturing facility.
ஏன் இது முக்கியம்Q1 is typically a high-margin period for FDC; maintaining growth here supports the company's target of outperforming the Indian Pharmaceutical Market growth rate while addressing operational costs.
Revenue (Q1 FY27): ₹715.35 கோடிNet Profit (Q1 FY27): ₹132.39 கோடிYoY Profit Growth: 9.1%Solar Investment: ₹45 லட்சம்Investment vs Net Worth: 0.02%
📅 குறுகிய காலம்The stock may see positive sentiment following the profit growth and EPS improvement, reflecting steady domestic performance.
📈 நீண்ட காலம்FDC remains a stable domestic-focused player with minimal debt; the green energy shift is a minor but positive step toward manufacturing efficiency.
⚠ அபாய எச்சரிக்கைகள்
US market product recalls (historical context)
High R&D spending impact on EBITDA
👀 கவனிக்க வேண்டியவை
Monitor the impact of the new therapeutic divisions (Nutrica) on overall margins and the progress of the Roha API plant's energy cost optimization through the new solar project.
FDC Limited: Maharashtra FDA Seizes 'Enerzal' Stock Over Misbranding Allegations
The Maharashtra Food & Drug Administration (FDA) conducted inspections at FDC's depots in Chhatrapati Sambhaji Nagar and Nagpur on June 3, 2026. During these visits, authorities seized stock of the company's popular brand 'Enerzal' and collected samples for examination regarding alleged misbranding. FDC has clarified that there is no material financial impact on operations as of now and business continues as usual. The company is awaiting the final examination order and intends to pursue legal recourse to resolve the matter.
முக்கிய அம்சங்கள்
FDA Maharashtra seized 'Enerzal' stock at Chhatrapati Sambhaji Nagar and Nagpur depots on June 3, 2026.The regulatory action is based on alleged misbranding of the product under food safety regulations.FDC reports no immediate material financial impact on the company's overall operations.Final examination orders from the Authority are currently pending.The company plans to take appropriate legal recourse once the final report is received.
👀 கவனிக்க வேண்டியவை
Investors should monitor the final FDA report as 'Enerzal' is a significant brand for FDC; any prolonged regulatory hurdle could impact brand equity. No immediate action is required as the company claims no material financial impact currently.
FDC Q4 FY26 PAT Surges 167% YoY to ₹103 Cr; EBITDA Margins Expand to 18.2%
FDC Limited reported a robust Q4 FY26 with revenue growing 18.9% YoY to ₹585 crores, driven by a sharp recovery in export markets and steady domestic growth. Net profit for the quarter skyrocketed by 167.4% to ₹103 crores, supported by a significant EBITDA margin expansion from 11.0% to 18.2%. While the full-year FY26 revenue growth was modest at 3%, the Q4 performance highlights a strong turnaround in the US business, which grew 283% YoY. The company also received US FDA approval for Fluconazole Tablets, strengthening its export pipeline.
முக்கிய அம்சங்கள்
Q4 PAT grew 167.4% YoY to ₹103 crores; EPS increased to ₹6.35 from ₹2.38EBITDA margins expanded by 720 bps YoY to 18.2% in Q4 FY26 due to operational efficienciesExport Formulations (US) revenue surged 283.1% YoY in Q4 to ₹39 croresDomestic Formulations business (78% of Q4 sales) grew 8.5% YoY to ₹452 croresFull year FY26 revenue reached ₹2,171 crores with a consolidated PAT of ₹281 crores
👀 கவனிக்க வேண்டியவை
Investors should view the sharp margin expansion and US business recovery as strong positives; the focus should remain on whether the domestic segment can maintain its Q4 growth momentum.
FDC Q4 Net Profit Surges 122% YoY to ₹107 Crore; Revenue Up 17%
FDC Limited reported a robust performance for Q4 FY26, with standalone revenue growing 17.1% YoY to ₹564.36 crore. Net profit for the quarter saw a significant jump of 122% YoY, reaching ₹107.07 crore, driven by strong operational performance and higher other income. For the full year FY26, the company recorded a net profit of ₹285.92 crore, up from ₹273.63 crore in FY25, despite a one-time exceptional charge of ₹20.79 crore related to new labor code provisions. The company maintains a strong balance sheet with total equity of ₹2,492.64 crore.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue from operations rose 17.1% YoY to ₹564.36 crore from ₹482.00 crore.Q4 FY26 Net Profit spiked 122% YoY to ₹107.07 crore compared to ₹48.22 crore in the previous year.Full-year FY26 EPS increased to ₹17.56 from ₹16.81 in the prior fiscal year.Recognized a one-time exceptional expense of ₹2,078.91 lakhs for estimated obligations under New Labour Codes.Other income for the quarter significantly increased to ₹47.16 crore from ₹31.43 crore YoY.
👀 கவனிக்க வேண்டியவை
Investors should take note of the strong Q4 recovery and margin expansion, which suggests improved operational efficiency. The company remains a stable pharmaceutical play with consistent dividend payouts and a debt-free balance sheet.
FDC Receives USFDA Approval for Cefixime Oral Suspension (100mg/5mL and 200mg/5mL)
FDC Limited has received Abbreviated New Drug Application (ANDA) approval from the United States Food and Drug Administration (USFDA) for Cefixime for Oral Suspension USP. The approval covers two dosage strengths: 100 mg/5 mL and 200 mg/5 mL. This regulatory milestone allows the company to market this antibiotic in the United States, expanding its international product portfolio. This development is expected to contribute to the company's export revenue growth in the highly regulated US market.
முக்கிய அம்சங்கள்
Granted ANDA approval by the USFDA for Cefixime for Oral Suspension USP.Approval includes two specific strengths: 100 mg/5 mL and 200 mg/5 mL.The product is a cephalosporin antibiotic used to treat various bacterial infections.Strengthens FDC's presence and product offerings in the US pharmaceutical market.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's commercialization strategy and launch timeline for this product in the US market. This approval is a positive indicator of FDC's regulatory compliance and potential for international revenue growth.
FDC Limited Faces GST Inspection at Mumbai Corporate Office
The Goods & Service Tax (GST) Department of Maharashtra initiated an inspection and search at FDC Limited's corporate office in Mumbai on February 10, 2026. The proceedings, which commenced at 16:15 hours, are focused on tax payments, input tax credit (ITC) claims, and refunds under the MGST Act, 2017. The company has stated that business operations continue as usual and there is no immediate financial impact from the initiation of this search. FDC is currently cooperating with the authorities and will disclose any material developments upon the conclusion of the inspection.
முக்கிய அம்சங்கள்
GST Department initiated search proceedings at FDC's Mumbai corporate office on February 10, 2026Inspection relates to tax payments, input tax credit claims, and refund processes under Section 67 of MGST ActCompany reports zero immediate financial impact and no disruption to ongoing business operationsFDC is extending full cooperation to the Deputy Commissioner of State Tax, Maharashtra
👀 கவனிக்க வேண்டியவை
Investors should monitor for any follow-up disclosures regarding tax demands or penalties resulting from this search. While operations are unaffected, regulatory scrutiny can lead to short-term sentiment-driven volatility.
FDC Q3 FY26 Results: Revenue Flat at ₹465 Cr, PAT Declines 23.6% YoY to ₹28 Cr
FDC Limited reported a stagnant Q3 FY26 with revenue from operations at ₹465 crore, a marginal 0.1% YoY growth. Profit After Tax (PAT) saw a sharp decline of 23.6% YoY to ₹28 crore, primarily due to exceptional items and a 5.2% contraction in the core Domestic Formulations business. While the domestic segment struggled with lower sales of top brands like Zifi and Electral, the Export Formulations segment provided a silver lining with 55% YoY growth. EBITDA margins showed slight improvement, rising to 11.2% from 10.1% in the previous year.
முக்கிய அம்சங்கள்
Revenue from operations remained flat at ₹465 crore (+0.1% YoY), while 9M FY26 revenue fell 1.9%.PAT dropped 23.6% YoY to ₹28 crore, with EPS declining from ₹2.28 to ₹1.74.Domestic Formulations, contributing 80% of revenue, declined 5.2% YoY to ₹369 crore.Export Formulations grew 55% YoY to ₹71 crore, driven by a 199% surge in US sales to ₹25 crore.EBITDA increased 12.1% YoY to ₹52 crore, with margins expanding 110 bps to 11.2%.
👀 கவனிக்க வேண்டியவை
Investors should remain cautious as the company's primary domestic engine is showing signs of weakness in its flagship brands. While the US FDA approvals and export growth are positive, the significant drop in bottom-line profit warrants a wait-and-watch approach for signs of domestic recovery.
FDC Limited Sets Feb 11, 2026, as Record Date for First Interim Dividend of FY 2025-26
FDC Limited has officially designated February 11, 2026, as the record date for its first interim dividend for the financial year 2025-26. This date is used to identify the shareholders eligible to receive the dividend payment. The announcement follows the company's regulatory compliance under SEBI (LODR) Regulations, 2015. While the specific dividend amount per share was not detailed in this specific record date filing, it confirms the upcoming cash distribution to eligible investors.
முக்கிய அம்சங்கள்
The record date for the first interim dividend of FY 2025-26 is fixed as Wednesday, February 11, 2026.The notification is issued pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Only shareholders whose names appear in the company's register as of the record date will be eligible for the payout.
👀 கவனிக்க வேண்டியவை
Investors looking to qualify for the dividend should ensure they hold the shares in their demat account before the ex-dividend date. Current shareholders should monitor for the specific dividend amount to assess the yield on their investment.
FDC Declares ₹5 Interim Dividend; Q3 Consolidated Net Profit Declines to ₹28.30 Crore
FDC Limited has declared a first interim dividend of ₹5 per equity share for FY 2025-26, with the record date set for February 11, 2026. The company's consolidated revenue for Q3 FY26 remained flat at ₹464.71 crore compared to ₹464.11 crore in the same quarter last year. Consolidated net profit for the quarter fell by 23.6% to ₹28.30 crore, down from ₹37.04 crore YoY. This decline was significantly impacted by a one-time exceptional expense of ₹20.79 crore related to the implementation of New Labour Codes.
முக்கிய அம்சங்கள்
Declared an interim dividend of ₹5 per share on a face value of ₹1 (500% payout).Consolidated Q3 revenue stood at ₹464.71 crore, showing negligible growth from ₹464.11 crore YoY.Net profit (consolidated) decreased to ₹28.30 crore from ₹37.04 crore in the previous year's quarter.Recognized a one-time exceptional cost of ₹20.79 crore due to regulatory changes in wage definitions under New Labour Codes.Standalone EPS for the quarter declined to ₹1.67 from ₹2.24 in Q3 FY25.
👀 கவனிக்க வேண்டியவை
Investors should focus on the steady dividend yield but remain cautious regarding the stagnant top-line growth. The profit dip is largely due to a non-recurring regulatory expense, so underlying operational efficiency should be monitored in the coming quarters.
FDC Receives USFDA Approval for Fluconazole Tablets in Multiple Strengths (50mg to 200mg)
FDC Limited has received Abbreviated New Drug Application (ANDA) approval from the USFDA for Fluconazole Tablets USP. The approval covers four specific dosage strengths: 50 mg, 100 mg, 150 mg, and 200 mg. This regulatory milestone allows the company to market and sell this antifungal medication in the United States. This development is expected to strengthen FDC's international product portfolio and contribute to its export revenue growth in the highly regulated US market.
முக்கிய அம்சங்கள்
Received USFDA approval for Fluconazole Tablets USP on January 9, 2026.Approval encompasses four dosage strengths: 50 mg, 100 mg, 150 mg, and 200 mg.Expands the company's footprint in the US pharmaceutical market.Fluconazole is a widely used antifungal medication, indicating a significant market opportunity.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for FDC's export business. Monitor the company's upcoming quarterly results for commentary on the commercial launch and market share expectations in the US.
FDC Limited Receives GST Demand Notice of ₹15.61 Crore for FY 2021-22
FDC Limited has received a demand notice from the GST Department, Maharashtra, totaling ₹15.61 crore for the financial year 2021-22. The demand includes a differential tax of ₹8.42 crore, interest of ₹6.35 crore, and a penalty of ₹0.84 crore due to alleged misclassification of tax rates. The authority claims the company charged 18% GST instead of the applicable 28% plus compensation cess. FDC intends to contest the order through legal remedies and believes there will be no material financial impact on its operations.
முக்கிய அம்சங்கள்
Total demand of ₹15.61 crore received from Deputy Commissioner of State Tax, Mumbai.Demand consists of ₹8.42 crore tax, ₹6.35 crore interest, and ₹84.22 lakh penalty for FY 2021-22.Allegation involves misclassification of GST rates, charging 18% instead of the required 28% plus cess.Company plans to seek legal remedy and contest the order in its entirety.Management does not foresee any material financial impact on account of this order.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the legal appeal as a final unfavorable ruling would result in a cash outflow of ₹15.61 crore. No immediate panic is necessary as the company is actively contesting the demand.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
